Costimulatory Molecule Blockade For The Treatment Of Graft-Versus-Host Disease
Share This:
                           

About The Author

Scott S. Graves is a senior staff scientist at the Fred Hutchinson Cancer Research Center in the Division of Clinical Research. He has expertise in immune tolerance mechanisms, co-stimulatory molecule blockade, molecular biology, genetic typing, pre-clinical animal modeling and graft versus host disease. In his lab, they conduct hematopoietic cell and kidney transplantation studies, assist in surgery and animal medical care, and protocols, produce and test in large animal model monoclonal antibodies and fusion proteins. 

                       

Costimulatory Molecule Blockade For The Treatment Of Graft-Versus-Host Disease

Allogeneic hematopoietic stem cell transplantation (HCT) has been widely used to treat both malignant and nonmalignant hematological disorders. Despite remarkable success, one complication that occurs in up to approximately 50% of patients undergoing allogeneic HCT is graft-versus-host disease (GVHD), of which there are two forms. These are acute GVHD, usually developing within 100 days, and chronic GVHD, developing 100 days and beyond after HCT. Both are the result of immune reactions of donor lymphoid cells to cellular targets on host...

Read more